PT-141 Bremelanotide 10mg
PT-141 (Bremelanotide) 10mg
Bremelanotide formerly known as PT-141 and tentative brand name Rekynda, is a peptide drug which has been under development by Palatin Technologies as a treatment for female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury. As of December 2014, Palatin is conducting a human phase III study using a subcutaneous drug delivery system that appears to have little effect on blood pressure.
All products are sold for research purposes only
Not for human consumption